[artículo] 
inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 61-68

Título :	Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment
Tipo de documento:	texto impreso
Autores:	John D. Roache, Autor ; John Grabowski, Autor ; Joy M. Schmitz, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 61-68
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Afecto, Estimulantes del sistema nervioso central, Trastornos relacionados con la cocaína, Frecuencia cardíaca, Metilfenidato.
Resumen:	Two experiments examined the effects of methylphenidate in male and female patients enrolled in an outpatient treatment program for primary cocaine dependence. The first study was a component of a double-blind efficacy trial wherein 57 patients were first tested in a human laboratory for their initial responsiveness to medication. Patients were randomly assigned to receive either placebo or methylphenidate treatment and received their first dose in the human laboratory environment before continuing in outpatient treatment.
Link:	./index.php?lvl=notice_display&id=31233

[artículo] Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment [texto impreso] / John D. Roache, Autor ; John Grabowski, Autor ; Joy M. Schmitz, Autor . - 2023 . - pp. 61-68.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 61-68

Palabras clave:	Afecto, Estimulantes del sistema nervioso central, Trastornos relacionados con la cocaína, Frecuencia cardíaca, Metilfenidato.
Resumen:	Two experiments examined the effects of methylphenidate in male and female patients enrolled in an outpatient treatment program for primary cocaine dependence. The first study was a component of a double-blind efficacy trial wherein 57 patients were first tested in a human laboratory for their initial responsiveness to medication. Patients were randomly assigned to receive either placebo or methylphenidate treatment and received their first dose in the human laboratory environment before continuing in outpatient treatment.
Link:	./index.php?lvl=notice_display&id=31233